Psoriasis cream could tame lupus skin flares

NCT ID NCT06661213

ENROLLING_BY_INVITATION Disease control Sponsor: Northwestern University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tests whether tapinarof cream, already approved for psoriasis, can improve skin lesions in people with cutaneous lupus. Ten adults with active lupus lesions will apply the cream daily for 16 weeks. Researchers will measure changes in skin activity and study immune cells to understand how the treatment works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tapinarof cream (VTAMA)
What this could lead to: If it works, this could point toward a new topical treatment for cutaneous lupus skin lesions.
What could go wrong: This is a very early, small trial with only 10 people. It may not show clear improvement, and results may not apply to all lupus patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUTANEOUS LUPUS ERYTHEMATOSUS

Contacts and locations

Show contact details

Locations

Northwestern University Department of Dermatology

Chicago, Illinois, 60611, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.